Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $18.94M |
| EBITDA | $-221.49M |
| Operating Margin | 0.00% |
| Return on Equity | -50.30% |
| Return on Assets | -31.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.00 |
| Price-to-Book | 3.37 |
| Price-to-Sales (TTM) | 25.86 |
| EV/Revenue | 11.55 |
| EV/EBITDA | -1.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.46M |
| Float | $48.09M |
| % Insiders | 0.42% |
| % Institutions | 112.64% |
Volatility is currently contracting
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could help corroborate its earlier data. Additionally, if CLN-978 becomes viable for more patients with a manageable safety profile, the potential repeat dosing also seems promising for better efficacy.
Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter.
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline.
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the International.
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026
Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CGEM and any ticker you trade — then tracks every position and per-strategy win rate.
